NEW YORK (360Dx) – Baebies said on Thursday that it has inked a bilateral distribution agreement with Trivitron’s Labsystems Diagnostics to deliver a wider range of newborn screening solutions across several global markets.
Under the agreement, Baebies will distribute Labsystems’ newborn screening products in the US after obtaining regulatory clearance. Labsystems will distribute Baebies’ FDA-cleared and CE-marked Seeker platform internationally.
Financial terms of the deal were not disclosed.
Baebies' Seeker is a high-throughput laboratory solution for newborn screening and is configured to perform testing for certain lysosomal storage diseases.
Labsystems produces the NeoMass AAAC kit used with tandem mass spectrometry to detect concentrations of amino acids, free carnitine, acylcarnitines, succinylacetone, and argininosuccinic acid. Its NS 2400 integrated robotic high-throughput platform is used to conduct enzymatic assay and immunoassay tests. Both are CE marked and commercialized in many parts of the world.
Baebies CEO Richard West said in a statement, “At this time, our newborn screening customers have only a single solution for many of their newborn screening tests." Its deal with Labsystems enables it to offer "the latest solutions and to provide a comprehensive offering" to its customer base, West added.
This first distribution agreement for the firm enables the expansion of its test offerings in the US and provides a means to reach other parts of the world with its products, Baebies said.